On May 24, an FDA advisory committee will meet to discuss the safety profile of Awiqli (insulin icodec), Novo Nordisk’s long-lasting insulin, after a study showed the drug poses an increased risk of ...
For Novo Nordisk to gain approval in the U.S. for its groundbreaking Awiqli (insulin icodec), it will have to first pass muster with a panel of experts next month, according (PDF) to a notice in the ...
Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...
An FDA advisory committee voted 7-4 against Novo Nordisk’s experimental weekly insulin shot after a study found elevated hypoglycemia risks and no additional benefits from the candidate. The therapy, ...
The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec) injection, if approved, has the potential to be the first once-weekly basal insulin ...
Novo Nordisk's resubmission for Awiqli is based on the ONWARDS Phase IIIa program, involving over 4,000 adults with type 2 diabetes. Awiqli aims to reduce basal insulin injections from 365 to 52 ...
On Sunday in Chicago, Dr. Athena Philis-Tsimikas, vice president of San Diego’s Scripps Whittier Diabetes Institute, helped deliver positive news for the estimated 7 million Americans who take insulin ...
Awiqli ® (insulin icodec) injection, if approved, has the potential to be the first once-weekly basal insulin treatment available in the US for adult type 2 diabetes In adults with type 2 diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback